Company Active LTD

Company profile

Ridgeway Biologicals Limited

Bot Verification

Ridgeway Biologicals Limited is a UK company with status active founded in 2003 based in South East England.

CRN
04897974
Founded
2003
Age
22

Overview

Legal name
RIDGEWAY BIOLOGICALS LIMITED
Region
South East England
Registered address
EXPLORER HOUSE, MERCURY PARK WYCOMBE LANE
WOOBURN GREEN
HIGH WYCOMBE
BUCKINGHAMSHIRE
ENGLAND
HP10 0HH
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

1 level 1 ultimate controller
1
Company Active LTD
Ridgeway Biologicals Limited
CRN 04897974
2
Direct and ultimate controller Active LTD

Company events

Reference milestones and recent Companies House filing stream events.

6 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

02 Sep
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

19 Aug
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

03 Oct
2024

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzQzODI2ODUyMGFkaXF6a2N4

Published 03 Oct 2024 08:51

12 Sep
2003

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2015
Funded years
2015
Age at first award
11 years

Projects

2015 Collaborative R&D Lead participant

Development of autogenous vaccines for the control of amoebic gill disease in farmed salmon

1 May 2015 to 31 Jul 2019

Awarded
£296,294
Total cost £519,120

Amoebic gill disease (AGD) is a new disease emerging in farmed salmon across the world including Scotland and Ireland. The amoeba colonise the gills of fish causing inflammation which can lead to suffocation of the fish. The project brings together scientists with expertise in AGD at the Institute of Aquaculture, University of Stirling; Marine Harvest Sco...

2015 Collaborative R&D

Validation of PCR technology for the development of autogenous vaccines for the control of viral diseases

1 Apr 2015 to 31 Mar 2018

Awarded
£91,533
Total cost £152,556

The ability to rapidly produce vaccines in response to bacterial and viral disease outbreaks in livestock is of significant economic benefit to the farming industry. The UK regulatory framework for vaccine production dictates that rapid response vaccines can only be manufactured as farm-specific (autogenous) vaccines (AVs). AVs can be produced cost-effect...

Product types

Collaborative R&D